Evolus
EOLS11.740
▲0.240
▲2.09%
- 最高位
- 11.790
- 最低位
- 11.510
- 開市價
- --
- 前收市價
- 11.500
- 成交量(千)
- 3.37
- 成交額(百萬)
- 0.39
- 買入
- 11.760
- 賣出
- 11.790
- 每手股數
- --
- 市值(百萬)
- 658.02
- 市盈率
- --
- 息率
- --
- 差價
- --
- 52週高低
- 14.340 - 5.061
所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。
企業資料
- 公司名稱
- Evolus
- 證券代碼
- EOLS.US
- 所屬板塊
- Drug Manufacturers - Specialty & Generic
- 公司業務
- Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company generates product revenue from the sale of Jeuveau in the US.
- 發行量
- 56045240
- 公司總部
- 520 Newport Center Drive, Suite 1200
- 公司網址
- https://www.evolus.com
- 公司電郵
- IR@Evolus.com
- 公司電話
- +1 949 284-4555
暫無內容
關於
Evolus(EOLS.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company generates product revenue from the sale of Jeuveau in the US.
詳細公司背景可參考: https://www.evolus.com。